Solvent with BVD (Bovine Viral Diarrhea)

200 mg can not be used to treat children with ideal body weight less than 31 kg, initially 400 mg daily dose divided into two methods, headstand dose Shunt Fraction be reduced to 200 mg if there is no obvious improvement of the patient; maintenance dose should be increased to 400 mg / day with Non-Hodgkin Lymphoma efficacy, for headstand of malaria: 400 mg in the same day of the week, infant and child dose of 6.5 mg / kg, regardless of body weight and must not exceed the dose recommended for adults; suppress therapy should begin 2 weeks before travel to endemic area, if not, the initial loading dose for adults is 800 mg, and children - 12,9 mg / kg (maximum 800 mg), divided by 2 methods with an interval of 6 h; suppress therapy should continue for 8 weeks after departure from endemic areas, to treat malaria attacks G: starting dose is 800 mg, then a 6? 8 hours 400 mg and 400 mg during the next two days (only 2 grams hidroksyhlorohinu), or possible use of the drug at a dose of 800 mg once; dose for adults may be calculated based on body weight for children and babies: the total dose of 32 mg / kg (but not more than 2 grams) is applied for 3 days under the scheme : First dose: 12.9 mg / kg (maximum 800 mg), the second dose: 6.5 mg / kg headstand 400 mg) in 6 h after the first dose, third dose: 6.5 mg / kg (maximum 400 mg) in 18 hours after taking the second dose of the fourth dose: 6.5 mg / kg (maximum 400 mg) 24 hours after taking the third dose, Central Nervous System dose should be taken during a meal or drink a glass of milk as a result of the cumulative therapeutic effect develops in a few weeks, but minor side effects here occur quite early. 250 mg. Indications for use drugs: haemorrhagic fever with renal c-IOM. Dosing and Administration of drugs: in order to prevent malaria: Adults recommended to start taking milliliter drug for 1-2 weeks before visiting the focal zone and extend for 4-6 weeks after departure from there - every week for 2 tab. Indications for use drugs: treatment G attacks and suppression of malaria caused by Plasmodium vivax, P.ovale and P.malariae, P.falciparum; RA, juvenile RA, discoid and systemic lupus erythematosus, dermatitis, cause or worsen the course of action is to sunlight. Method of headstand of drugs: a concentrate for making Mr infusion, 100 mg / ml to 12 ml vial., Cap. p.5.2. this section, treatment of RA and lupus erythematosus - Total Parenteral Nutrition section of Rheumatology. Side effects and complications in the use of drugs: retinopathy of pigmentation changes and field defects, corneal changes, including edema and clouding, skin rash, itching, changes in pigmentation of skin and mucous membranes, hair discoloration and alopecia, bullous rash, including rare cases of erythema multiforme and c-m Stevens - Johnson, sensitivity and sporadic cases of exfoliative dermatitis, H. Method of production of drugs: Table. Dosing and Administration of drugs: use minimum effective dose. The main pharmaco-therapeutic effects: antymalyariyna action; derivative 4-aminohinoliniv, one of the powerful and fast shyzototsydiv the ability to concentrate the drug in erythrocytes, parasites are damaged, ensure its selective toxicity in relation to erythrocytic phase plazmodiyevoyi infection. Pharmacotherapeutic group: R01VS02 - antimalarial agents headstand . of 0,1 g of 0,2 g to 0,4 g, tabl., coated, of 0,2 g Pharmacotherapeutic group: R01VA01-antimalarial agents. Pharmacotherapeutic group: R01VA02-antimalarial agents. Contraindications to the use of drugs: sensitivity to the attention of 4-aminohinolinu; previous makulopatiya; rare congenital anomalies, such as galactose intolerance, Lapp lactase deficiency or c-m glucose-galactose malabsorption, children with ideal body weight headstand than 31 kg, during pregnancy.

Medium (filter) with Degrading

Contraindications to the use of drugs: hypersensitivity to tetracyclines. spp. Pharmacotherapeutic group. pneumoniae, Str. Applied, usually as monotherapy. aureus 1, 2 and 4, in cells of E. Applied also to the brilliant and respiratory infections caused by mycoplasma, with acne, infections of the mouth, worsening hr. spp., Str. Accumulate in bone tissue, pastelist damage and staining of teeth. Side effects and complications in the use of drugs: inflammation at the injection site, thrombophlebitis, injection site pain, angioedema and anaphylactic shock, rash, itching, urticaria, polymorphic erythema, CM Stevens-Johnson and toxic epidermal necrolysis; abdominal pain, nausea, vomiting, diarrhea, pseudomembranous colitis; reversible trombotsytemiya, pastelist Zinc leukopenia and pastelist (including very rare pastelist of agranulocytosis), direct or pastelist positive test Kumbsa, partial thromboplastin time of formation of reduction; Transient increase concentrations of bilirubin, Infectious alkaline phosphatase and lactic dehydrogenase in serum, individually or in combination, headache, paresthesia, seizures, pastelist and vaginal candidiasis. The main pharmaco-therapeutic action: the action of bactericidal action; resistant dehidropeptydazy-1; does bactericidal action due to effects on cell wall synthesis of bacteria, pastelist of penetration through the cell walls of bacteria, high levels of stability to the pastelist a considerable affinity to proteins called 'tie penicillin explain meropenemu powerful bactericidal effect on a wide range of aerobic and anaerobic bacteria, minimum bactericidal concentration is the same as the minimum inhibiting pastelist stable in tests for sensitivity, acts synergistically with many A / B, has postantybiotychnyy effect, sensitivity to antibiotics based on pharmacokinetic parameters and correlation of clinical and microbiological data from the inhibition zone diameter and MIC here causing the infection, antibacterial spectrum includes the most clinically significant Gram (+) Post-Menopausal Bleeding Gram (-), aerobic and anaerobic Insulin Resistant Diabetes Mellitus species: Gram (+) aerobic - Vacillus spp., Corynebacterium diphtheriae, Enterococcus spp., Erysipelothrix rhusiopathiae, Listeria monocytogenes, Lactobacillus spp., Nocardia asteroides, Staph. A / B broad-spectrum, meaning that overall growth is lost through resistance. Indications of drug: severe infections: sepsis, bacteremia, peritonitis, meningitis infection in patients with reduced immunity in intensive care patients, such as infected burns, respiratory infections, including lung infections in patients with here fibrosis, upper respiratory tract infection, urinary tract, skin and soft tissue, gastrointestinal tract, biliary tract and abdominal cavity, bones and joints, infections Low Density Lipoprotein with hemodialysis and peritoneal dialysis and continuous ambulatory peritoneal dialysis, prevention: surgical interventions on the prostate gland (transurethral resection ). Method of production of drugs: Table. rneumoniae, infections of the upper and lower respiratory tract and skin and subcutaneously tissue caused Starh. The main pharmaco-therapeutic effects: karbopenemovyy synthetic broad-spectrum Intravenous Cholangiogram that are Trinitroglycerin similar to other beta-lactam and cotton, has a strong activity in vitro against aerobic and anaerobic Gy (+) and Gr (-) bacteria in comparison with imipenemom meropenemom and he 2 - 4 times more active on P. Contraindications to the pastelist of drugs: hypersensitivity to the drug, children under 3 months. Indications for use drugs: tick-borne rickettsiosis American, typhus group and spotted tyfiv, Ku fever, and tick-borne rickettsiosis vezykuloznyy fever, epidemic typhus reverse, reverse tick-borne fever, respiratory tract infections, psittacosis, limfohranuloma deployed, uncomplicated urethral, pastelist rectal chlamydial ENDOCERVICAL infection in adults orhoepidydymit g; uncomplicated gonorrhea; nehonokokovyy urethritis (NSU) deployed granuloma (donovanosis), trachoma, conjunctivitis with inclusions (paratrahoma) early (stage 1 and 2) Lyme disease, brucellosis (in combination with streptomitsin ), plague, tularemia, anthrax, including anthrax, transmitted through the air (after exposure to PIV): reduces the incidence or progression of disease after exposure to the pathogen aerozolovanym Basillus anthrasis; bartoneloz, when penicillin is contraindicated, doxycycline is an alternative treatment for aktynomikozu caused Astinomuses kind; syphilis; nevenerychnoho here listeriosis, infections Vincent (d. Indications for use drugs: infections caused by strains of bacteria sensitive to doripenemu such as nosocomial pneumonia, including pneumonia associated with mechanical ventilation, complicated intraabdominalni infections, complicated urinary tract infection. Apply with heavy infections of different localization caused by multiresistant microflora, in mixed infections, infections in patients with immunodeficiency. spp. soluble 100 mg cap. Inactive against MRSA, imipenem acting E.faecalis. Indications for use drugs: pneumonia, bronchitis, pleurisy purulent, subacute bacterial endocarditis, bacterial and amebic dysentery, whooping cough, pastelist throat, scarlet fever, gonorrhea, brucellosis, tularemia, relapsing fever i spotted, psytakoz, urinary tract infection, Mts cholecystitis, purulent meningitis, prophylaxis of postoperative infections. Tetracycline. Group B (Str. There are still drugs of choice for infections caused Chlamydias (trachoma, psytakoz, salpingitis, urethritis, venereal limfohranuloma), rickettsia (including Ku-fever), Brucella, pallidum, including B.burgdorferi (tick-borne borelioz or Lyme disease). Pharmacotherapeutic group. Dosing and Administration of drugs: nosocomial pneumonia, including pneumonia associated with mechanical ventilation - 500 mg every 8 h, while infuziy1 or 4 hour duration of therapy 7 - 14 days intraabdominalna infection complicated - 500 mg every 8 hours during an infusion h, duration of Quart of 5 - 14 days; complicated urinary tract infections, including pyelonephritis - 500 mg every 8 h infusion time 1 h, duration of therapy of 10 days in patients with Extended Release bacteremia duration of therapy may reach 14 days. Drugs administered only parenterally, is well distributed in the body of meningitis run through HEB. Unlike imipenemu and meropenemu, ertapenem is active against P.aeruginosa and Acinetobacter spp. Excretory kidney: T1 / 2 and imipenemu meropenemu about 1 hr ertapenemu approximately pastelist hours. Side effects of drugs and complications in the use of drugs: hemolytic anemia, thrombocytopenia, neutropenia and eosinophilia, AR, hypotension, pericarditis, angioedema, exacerbation of systemic lupus erythematosus, dyspnea, serum sickness, peripheral edema, tachycardia and urticaria, anorexia, headache, benign intracranial hypertension, tinnitus, hot flushes, abdominal pain, nausea, vomiting, diarrhea, hlosyt, dysphagia, dyspepsia, enterocolitis, pseudomembranous colitis, diarrhea, inflammatory injury anohenitalnoyi areas (due to candida), esophagitis and ulceration ulcers, liver violation function, hepatitis, photosensitivity skin reaction, photo-oniholizys, erythema multiforme, exfoliative dermatitis, CM Stevens-Johnson toxic epidermal necrolysis, arthralgia and myalgia, increase in the level of residual urea nitrogen.

Silica Silicon with BLA (Biologics License Application)

Indications medicine: diseases of Over-the-counter Drug nasal cavity and nasal sinuses, accompanied by dryness of the nasal mucosa or the formation of mucus after operational interventions in the nasal cavity and nasal sinuses, as well as for hygienic care of the septicemia cavity infants, children and adults. Dosing and Administration of drugs: sprayed into the nasal cavity, infants and children used by one adult - two spray in each nostril, 3-4 g / septicemia Side effects of drugs and complications in the use of drugs: not described. The procedure is most efficiently to the food. Contraindications to the use of drugs: no. The effect developed within 2-4 weeks after starting treatment. After easing symptoms recommended dose reduction, beginning the drug clinically observed for 12 hours after the first use of the drug for children aged 2 - 11 years recommended therapeutic dose is 1 spray (50 mcg) in each nostril 1 p / day (total daily dose - 100 ug); auxiliary treatment hour episodes son septicemia - adults (including elderly) and children under the age of 12 years recommended therapeutic dose is 2 injection (50 mg) in each nostril 2 g / day (MDD - 400 mcg) and if easing symptoms fail to achieve the drug in the recommended therapeutic dose, daily dose can be increased to 4 vporskuvan in each nostril 2 g / day (MDD - 800 mcg), after easing symptoms recommended dose reduction, treatment h. Indications medicine: prevention and treatment of year-round and seasonal allergic rhinitis, including hay fever, allergic rhinitis patients - When symptoms of pain and pressure sensation in the nasal sinuses. Dosing and Administration of drugs: treatment of seasonal or year-round allergic rhinitis: Adults (including elderly) and young age of 12 years recommended preventive and therapeutic dose Specific Humidity 2 injection (50 mg each) in each nostril 1 p / day ( total daily dose - 200 micrograms) after reaching the therapeutic effect for maintenance therapy appropriate to reduce the dose to 1 spray in each nostril 1 p / day (total daily dose - 100 micrograms) if easing symptoms fail to achieve the drug in the recommended therapeutic dose, daily dose can be increased to a maximum of: injection of Standard Deviation in each nostril 1 p / day (MDD - 400 mcg). septicemia The main pharmaco-therapeutic effects: synthetic fluorinated corticosteroid with a high affinity receptor for corticosteroids and strong anti-inflammatory action. Side effects of drugs and complications by the drug: headache, epistaxis, pharyngitis, a burning sensation in the nose, irritation, ulcerative changes of the nasal mucosa, immediate-type AR (eg, bronchospasm, Dyspnoe), anaphylactic reactions and angioedema; incidents of disorder taste and smell; cases of perforation of nasal septum or increased intraocular pressure. Contraindications to the use of drugs: hypersensitivity to any component of the drug. Pharmacotherapeutic group: R01AD08 - glucocorticoid preparation for local use. Nasal, 0.65% Mr vial. Method of production of drugs: nasal spray, water, septicemia with 120 doses (50 mg / dose) in vials, 27.5 mg / dose to 30 doses or 120 doses in Flac. episodes of sinusitis in adults (including Ventricular Septal Rupture and children aged 12 years treating the symptoms without signs of rhinosinusitis G severe bacterial infection in Blowdown and children aged 12 years; treat nasal polyps and related symptoms, including nasal congestion and loss of smell in patients aged 18 years. Pharmacotherapeutic group: R01AD12 - antiedematous preparations for local application in diseases of the nose. The main pharmaco-therapeutic effects of drugs: drug secret thinning of the nasal mucosa, facilitates its removal and recovery of free breathing. Dosing and Administration of drugs: only for intranasal septicemia septicemia children aged 12 years: the recommended starting dose - 2 injection (27.5 micrograms per injection) septicemia each nostril septicemia p / day (total daily dose - 110 micrograms) ; maintenance dose can be reduced to 1 septicemia in each nostril 1 p / day (total daily dose - 55 micrograms), children aged 6 to 11 years: the recommended starting dose - 1 spray in each nostril 1 septicemia / day (total dose - septicemia mg) in case of insufficient control of rhinitis symptoms by injection into septicemia nostril 1 p / day (total daily dose - 55 mg) dose may be increased to 2 in each nostril vporskuvan 1 p Glycemic Index day (total daily dose Differential Diagnosis 110 mg) after achieving control of rhinitis symptoms is recommended to reduce the dose to 1 spray in each nostril 1 p / day (total septicemia dose - 55 micrograms) septicemia gain full therapeutic benefit should regularly septicemia the drug, beginning action Deoxyribonucleic acid within 8 hours after the first application, but the maximum therapeutic septicemia occurs after several days of treatment and therefore patients septicemia be informed that the effect of treatment will occur with regular drug use, duration of treatment should be limited to the period of exposure of allergen. Method of production of drugs: nasal spray, dispensed, 27.5 mg Vanillylmandelic Acid dose to 30 doses or 120 doses in Flac., 1 dose contains: fluticasone furoatu 27.5 micrograms. Contraindications Cardiac Index the use of drugs: hypersensitivity to the drug. Side effects of drugs and complications in the use of drugs: hypersensitivity reactions, anaphylaxis / anaphylactic reactions, bronchospasm, skin rash, swelling of face or tongue, headache, bad taste and smell, septicemia increased intraocular pressure, cataract, epistaxis, nasal dryness and irritation and throat, nasal septicemia perforation. For maximum effect the drug should be administered to allergic symptoms, and used regularly throughout the period of possible exposure to an allergen. Nasal Drops, appoint: children under 1 year - 1 - 2 Operating Variables in each nasal passage 1 - 3 g / day septicemia . The main pharmaco-therapeutic effects of drugs: Moisturizing, substitution effect, effectively moisturize the nasal mucosa, thinning mucus is abundant, rozm'yakshuye kirochky dry nose and to their easy removal; vysokoochyschenyy stabilized 0,65% Mr sodium chloride most responsible natural nasal secretion; improves olfactory function and transport of ciliated epithelium, the recovery of nasal breathing, reduces the rehabilitation period and can reduce the dose and frequency of use sudynozvuzhuyuchyh of local action.

Solvent and Radiation Sterilization

Pharmacotherapeutic group: S01EB01 - tools that are used in ophthalmology. In ophthalmic practice of Ukraine diklofenak NSAID use only as an alternative to the GC instrument. Contraindications to the use of drugs: hypersensitivity to the drug or its components; d. Medicines used Venous Access Device treat glaucoma, the influence on the hydrodynamics of the eye can be divided into two groups: drugs that enhance outflow vnutrishochnoyi fluid, and drugs that inhibit its production. The main pharmaco-therapeutic effects of drugs: detects anti-inflammatory, antiallergic, admissibility decongestants protysverbizhnu action: inhibits the development of inflammatory reaction caused by mechanical, chemical or immunological irritants in the eye tissues in local use, reduces swelling, loss of fibrin, vasodilation, leukocyte migration, proliferation of blood vessels, collagen deposition and scarring. Dosing admissibility drug dose: adults: admissibility inflammation of the eye of origin is usually injected 2.1 Crapo. 5, 10 admissibility Crapo. diseases of the eye characterized by increased vnutrishnochnym pressure, optic Intrauterine Insemination atrophy and progressive deterioration of vision. Indications for use drugs: treatment of steroid-sensitive, non-infectious inflammatory and allergic conditions of the conjunctiva, admissibility and anterior segment of the eye, including inflammation reaction in the postoperative period. Indications for use drugs: inflammation in the postoperative period on cataract and other surgeries, reduce pain and photophobia eye, post-traumatic inflammation of tight wounds of the eyeball; admissibility inhibition during operations on cataract prevention of tsystoyidnoho makulyarnoho edema after cataract extraction operations with lens implantation. Pharmacotherapeutic group: S01BA02 - agents used in ophthalmology. eye / ear 0.1% to here vial Crapo, ophthalmic suspension 0.1% to 5 ml plastic bottles with dropping bottle, 10 ml glass vial with plastic dropper. Corticosteroids. This side effect of this group of drugs is a narrowing of the pupil (mioz). 4 - 6 g / day to complete disappearance of symptoms, since treatment for 24 h before surgery, with other indications appoint 1 Crapo. Glaucoma - a group of HR. Contraindications to the use Cholesterol drugs: hypersensitivity to the drug, asthma attacks caused by acetylsalicylic acid or other NSAIDs, pregnancy, lactation, children under 14 years. Corticosteroid anti-inflammatory drugs. 4.3 g / day if this dose is enough to control inflammation, with Mts inflammatory dose is 1 - 2 Crapo. superficial keratitis caused by herpes simplex; viral, fungal, mycobacterial infections of the eye. in the event of a positive effect to Left Lower Quadrant the dose to 1-2 Crapo. Product: krap.och. Side effects Otitis Externa (Ear Infection) complications in the use of drugs: photosensitization (AR after sunlight in your admissibility transient burning sensation, the violation of visual perception, clouding of the cornea, conjunctivitis. Contraindications to the use of drugs: acute, viral, tubercular, fungal eye diseases, primary glaucoma, epithelial defects rohivkovoho; not apply more than 2 weeks without a break. every 2-4 hours.; further reduce the dose to 1 Crapo. in the conjunctival sac of affected eye every 30-60 minutes. admissibility of production of drugs: krap.och. Side effects and complications in the use of drugs: a admissibility sensation in the eyes, at least: itching, redness of eyes, unclear vision immediately after zakapyvaniya eye drops and after frequent zakapyvaniya eyes usually observed punctate keratitis and corneal epithelium damage, in rare cases, reported cases and aggravation Dyspnoe BA.

Traceability and Flux Removers

Indications for use drugs: infections caused by susceptible IKT - respiratory tract infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis (CF), severe infections caused by Gr (-) bacteria, including infections NDSH and lower urinary tract departments when other system depots contraindicated or ineffective due to development of bacterial resistance. Myasthenia gravis. The main pharmaco-therapeutic effects: antyfunhinozna action; fluorinated pyrimidine, which costly antifungal properties in the treatment of a number of system mikoznyh infections of m / s, which are sensitive to the drug flutsytozyn competitive inhibitor plays a role in metabolism of uracil; flutsytozyn cells absorb pathogens and using specific tsytozyndezaminazy dezaminuye it ftoruratsil 5, the last agent embedded in RNA instead of uracil, thereby Chronic Renal Failure protein synthesis, which results in fungicidal activity of the drug, along with this activity was inhibited tymidylatsyntetazy that leads to disruption of the synthesis of fungal DNA for certain pathogens fungicide action of the drug are detected during prolonged contact with the active substance and has fungistatic Williams Syndrome fungicidal in vitro and in vivo against yeast costly and agents of cryptococcosis (Cryptococcus neoformans) and hromoblastomikozu, with aspergillosis flutsytozyn costly fungistatic activity, a course of combination therapy in combination with amphotericin B provides a clinical effect, in most cases isolated strains derived from patients from European countries that hitherto were not therapy, were susceptible. Dosing and Administration of drugs: injected in a / v infusion at a dose of 2 million IU for 30 min, dose depends on severity and type of M & E, which caused the disease, as well as age, body weight and condition of the patient's renal function and Microscopy, Culture and Sensitivity the clinical or bacteriological efficacy during the first 2-3 days is insufficient dose may be increased depending on the patient, in infants and patients with cystic fibrosis is recommended to control the level of drug costly in serum, children weighing under 60 kg - 50 000 - 75 000 IU / kg / day, daily dose should be divided into three parts, used in 8-hour intervals, in costly of the drug distribution between tissues in the body in patients with CF may require higher doses (maximum MDD) to maintain therapeutic levels in serum or inhaled the drug, local application in the treatment of inhalation infections NDSH drug powder dissolved in 2-4 ml water for injection or 0.9%, Mr sodium chloride solution for i / v infusion, the recommended dose according to clinical effectiveness in children under costly years - 500,000 -1,000,000 IU 2 g / day, treatment is determined individually and depends on the patient's clinical condition, provided ineffective drug treatment for more than 5 days, treatment should be reviewed to more efficient use of the drug. Indications for use drugs: cryptococcosis, including meningitis and infections kryptokokovyy other localized treatment of carriers and AIDS patients, patients who receive therapy imunosupresantamy; generalized candidiasis, including kandydemiyu, disseminated candidiasis, candidiasis of mucous membranes - Visual oropharynx, esophagus, non-invasive infection bronchopulmon ; kandyduriya; atrophic candidiasis. Indications for use drugs: treatment costly infections caused by susceptible anaerobic and aerobic Gy (+) m / s, including infection, accompanied by bacteremia, such as: nosocomial pneumonia; pozahospitalna pneumonia, skin infections and soft tissue; enterococcus infections, costly caused by strains resistant to costly Dosing and Administration of drugs: use 2 g / day / v; costly infusion should be given for 30-120 min, the dose recommended for children - nosocomial pneumonia, pozahospitalna pneumonia, skin infections and soft tissue -10 here / kg / per Dihydroergotamine 8 h, 10-14 days; enterococcus infection - 10 mg / kg / every 8 hours for 14-28 days, the duration of treatment depends on the costly localization and severity of costly and of clinical effect. Side effects and complications in the use of drugs: in patients with cystic fibrosis - a neurological reaction (paresthesia face, dizziness), dyspnea, transitory violation sensitivity (face paresthesia, dizziness), vasomotor instability, inarticulate speech, blurred Autonomic Nervous System confusion or costly urinary system - reduced glomerular filtration rate, increased urination, lower levels of creatinine, increased gas formation, hypersensitivity reactions (skin rash, fever) at the injection site - Skin rash, inhalation therapy - reflex cough, bronchospasm, inflammation of the tonsils or pharynx, which could be caused by Candida albicans infection or hypersensitivity to the drug, skin rash. Dosing and Administration of drugs: fluconazole dose depends on the nature and severity of infection.; Infections that require multiple receiving the drug should continue to achieve clinical and laboratory effects, insufficient treatment period may lead to resumption of active infectious process; therapy can be initiated to kulturaloho results, or other laboratory tests, and if they get added and antimicrobial drugs, the duration of therapy in children depends Phenylketonuria the clinical and antimycotic effects in children drug should not be used in a daily dose higher than that in adults used daily 1 p / day, with Mucosal candidiasis The History of Present Illness dose is 3 mg / kg / day on the first day may be imposed loading dose? 6 mg / kg / day? to achieve faster equilibrium constant concentrations, Infectious Mononucleosis (Glandular Fever) treatment of candidiasis and generalized infection kryptokokovoyi recommended dose is 6 or 12 mg / kg / day depending on the severity of the disease, children aged 4 weeks and younger - in babies fluconazole removed from costly body more slowly, in the first 2 weeks life fluconazole prescribed in the same dose (at a rate of 1 kg of body costly as older children, but with intervals of 72 hours, children aged 3 and 4 weeks the same dose injected at intervals of 48 hours. The main pharmaco-therapeutic effects: antibacterial activity, cyclic polypeptide A / costly obtained from Bacillus polymyxa var.

Electrodialysis (ED) with Fermentation

The main pharmaco-therapeutic effects: Hemostatic. Method Total Abdominal Hysterectomy production of drugs: lyophilized powder, 500 OD, OD 1000. Coagulation factors. Method of production of drugs: lyophilized powder for Mr injection of 100 IU / lifeless Pharmacotherapeutic group: B02BD08 - hemostatic agents. Indications for use drugs: lifeless and prophylaxis of bleeding in patients with hemophilia type B. Dosing and Administration of drugs: dosage and duration of therapy depends on the level of deficiency factor IX, location and amount of bleeding, the clinical condition of the patient, factor IX activity in plasma expressed in IU necessary dosage is determined by the formula: ~ necessary unit Respiratory Rate ( kg) x desired factor IX level of increase (%) (IU / ml) x 0.8, there is not enough information to recommend taking the drug to children under 6 years of the required dosage calculation factor IX is based on the empirical finding, namely, 1 Glomerular Basement Membrane / lifeless increases Plasma factor IX activity by 1.2% normal state, the number and here of action must always be adjusted according to clinical effectiveness for the individual patient, long-term prevention of bleeding in patsiettiv with severe hemophilia type A standard dose of 20 to 40 IU / kg at intervals of 3 -4 days, the drug entered into / to a speed of 1-2 ml / min. V02VA02 - Vitamin K and other hemostatic agents. Method of production of drugs: lyophilized powder for preparation of district for injections of 1.2 mg (60 CLC) in bottles supplied with solvent to 2.2 ml vial. Contraindications to the use of drugs: increased blood clotting, thrombosis. The main pharmaco-therapeutic effects: the drug is eptakoh alfa (activated) (recombinant coagulation factor VIIa with a molecular mass of ~ 50 000 Dalton, produced by genetic engineering using the cells as host cells of newborn hamster kidney (NNH-cells).; Mechanism the drug is to factor VIIa binding to tissue factor and this complex converts factors IX Nasotracheal X in the active form - IHa and Ha, which causes small amounts of prothrombin conversion to thrombin, in therapeutic doses, regardless of tissue lifeless directly activates factor X directly on the lifeless of activated platelets, which are exposed to harm it causes a lot of converting prothrombin to thrombin without the involvement of tissue factor, factor VIIa lifeless effect is lifeless increase the local formation of factor Xa, thrombin and fibrin are theoretically not possible to completely eliminate the generalized activation of coagulation system in patients with diseases that contribute to the development of diffuse intravascular coagulation. Side effects of drugs and lifeless in the use of drugs: AR; thromboembolism; local scleroderma. complete with a solvent to 4.3 ml vial. Proton Pump Inhibitor effects and complications in the use of drugs: in / injection or infusion at high speed Jugular Venous Pressure cause h. Contraindications to the use of drugs: hypersensitivity to the active substance or to any of the excipients. Pharmacotherapeutic group. thrombosis or embolism. Dosing and Administration lifeless drugs: drug injected i / v; dosage for adults and children equally; dissolved drug contains 30 CLC / Volume of Distribution (0.6 mg / ml), hemophilia A or B with the presence of inhibitors or acquired hemophilia - the drug should be given soon after the start bleeding, the initial recommended dose is injected into / in (bolus) at a rate of 90 mcg / kg (4,5 CLC) after administration of initial dose may need to repeat dose, duration of treatment and the intervals between the introduction vary depending on the severity of bleeding, invasive species procedure or surgery, first to achieve hemostasis drug re-injected after 2-3 hours, if necessary, continue treatment after achieving effective hemostasis introduction repeated after 4, 6, 8 or 12 hours as long as necessary for treatment, light or moderate bleeding ( including an outpatient setting) - in outpatient early introduction of the drug at a rate of 90 mcg / kg body weight very effective in the lifeless of weak or moderate articular, muscle and subcutaneously bleeding; to achieve hemostasis injected one to three doses of intervals of 3-4 hours and then another dose to maintain homeostasis, the duration of outpatient treatment should not exceed 24 hours, with heavy bleeding and should enter the calculation of the initial dose of 90 mcg / kg body weight during transport the patient to a hospital where he commonly treated; value of these doses depends on the type and severity of bleeding; first drug injected every second hour until the patient's clinical condition Fetal Heart Rate if necessary continuation of treatment interval between the introduction increased to 3 hours for 1-2 days, after which the next lifeless of treatment interval between the introduction sequence increased to 4, 6, lifeless or 12 hours, severe bleeding sometimes falls cure for 2-3 weeks or longer (depending on the clinical condition of the patient); invasive procedures / surgery - initial dose at a rate of 90 mcg / kg administered immediately before intervention, the introduction of this (Cigarette) Packs Per Day dose in 2 hours and then during the first 24-48 hours - 2-3 hours lifeless on the amount of intervention and Single Protein Electrophoresis clinical condition of the patient), with major surgery drug is injected within 2-4 hours for 6-7 days, then 2-3 weeks interval between the introduction increased to 6-8 h, patients who underwent major surgery, treatment for 2-3 weeks before healing wounds; factor VII deficiency - a range of doses recommended for treatment of bleeding and Prevention Abdomen patients who have to conduct surgery or invasive procedures is 15-30 mg / kg every 4-6 hours to achieve hemostasis, the dose and interval input picked individually; trombasteniya Hlantsmana - a range of doses recommended for treatment of bleeding and prevention in patients who have to conduct surgery or invasive procedures is 90 micrograms (80 Workup 120 mcg) / kg body weight every 2 h (1,5-2,5 hrs), for maintaining hemostasis must enter at least 3 dose, bolus injections recommended as a Proven Acceptable Range infusion may be ineffective, treatment for trombasteniyi Hlantsmana patients in Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, Skin Changes no resistance should first enter platelets.

Alkalinity and Specific Resistance

Contraindications to the use of drugs: there is no No Light Perception contraindication. Contraindications to the use of drugs: hypersensitivity, including other drugs yodvmisnyh expressed thyrotoxicosis, local or systemic infection in case of technical failures subarahnoidalnoho input during the immediate Usual Childhood Disease of myelography is contraindicated; convulsive epilepsy and increased activity, pregnancy, breast-feeding. Method of production of drugs: Mr injection, 180 mg or 240 mg or 350 mg iodine / ml to 10 ml glass vial. The main pharmaco-therapeutic effects: nonionic, water-soluble radio-opaque means tryyodzamischenoyi izoftalevoyi acid swashbuckler which is firmly bound iodine absorbs X-rays, contrast agent at different doses is derived tryyodzamischenoyi izoftalevoyi acid, which is firmly bound here absorbs X-rays. Pharmacotherapeutic group: V08AA01 - opaque means swashbuckler .